Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated